Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for … – Nasdaq
|
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for …
Nasdaq Previously reported data from a Phase 1b clinical trial demonstrated that Inovio's cancer immunotherapy (INO-5150) slowed PSA rise in patients with biochemically recurrent prostate cancer. Additional analyses show clinically meaningful PSA … |
